Cite
MLA Citation
Benedikt Schoser et al.. “Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.” Lancet neurology, vol. 20, no. 12, 2021, pp. 1027–1037. http://access.bl.uk/ark:/81055/vdc_100146096740.0x00001a